{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:24:17Z","timestamp":1787228657748,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000902","name":"Pediatric Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000902","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024596","name":"Bayer Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003287","name":"Rally Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tranon.2026.102866","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:08:39Z","timestamp":1781784519000},"page":"102866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Combined inhibition of CDK4\/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcoma"],"prefix":"10.1016","volume":"71","author":[{"given":"Helen F.","family":"Gloege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1576-2796","authenticated-orcid":false,"given":"Maria Ana Isabel C.","family":"De Los Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Advaita","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2760-6888","authenticated-orcid":false,"given":"Madhav","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1354-8211","authenticated-orcid":false,"given":"Alejandra","family":"Aguilar-Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb O.","family":"Heaslip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Finstuen-Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigit","family":"McDannell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-1181","authenticated-orcid":false,"given":"Mohammad","family":"Tanhaemami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2003","authenticated-orcid":false,"given":"Kelly","family":"Klega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-910X","authenticated-orcid":false,"given":"Anne-Florence","family":"Blandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Crompton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102866_bib0001","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.21.00358","article-title":"Phase III trial adding Vincristine-Topotecan-Cyclophosphamide to the initial treatment of patients with nonmetastatic ewing sarcoma: a Children\u2019s Oncology Group report","volume":"39","author":"Leavey","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102866_bib0002","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/pbc.21618","article-title":"Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children\u2019s Oncology Group","volume":"51","author":"Leavey","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.tranon.2026.102866_bib0003","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/pbc.23040","article-title":"Risk of recurrence and survival after relapse in patients with Ewing sarcoma","volume":"57","author":"Stahl","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.tranon.2026.102866_bib0004","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.22.01815","article-title":"Randomized Phase III trial of Ganitumab with interval-compressed chemotherapy for patients with newly diagnosed metastatic ewing sarcoma: a report from the children\u2019s oncology group","volume":"41","author":"DuBois","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102866_bib0005","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1002\/cncr.30627","article-title":"Longitudinal follow-up of adult survivors of Ewing sarcoma: a report from the Childhood Cancer Survivor Study","volume":"123","author":"Marina","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102866_bib0006","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/2159-8290.CD-13-1037","article-title":"The genomic landscape of pediatric ewing sarcoma","volume":"4","author":"Crompton","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2026.102866_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive analysis of hypermutation in Human cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102866_bib0008","doi-asserted-by":"crossref","DOI":"10.1126\/science.aam8419","article-title":"Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors","volume":"361","author":"Anderson","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.tranon.2026.102866_bib0009","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102866_bib0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102866_bib0011","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-14-0622","article-title":"Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations","volume":"4","author":"Tirode","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2026.102866_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004475","article-title":"The genomic landscape of the Ewing Sarcoma Family of tumors reveals recurrent STAG2 mutation","volume":"10","author":"Brohl","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.tranon.2026.102866_bib0013","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1699 pediatric leukemias and solid tumors","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102866_bib0014","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u201cundruggable\u201d cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2026.102866_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216042","article-title":"Inhibition of the PI3K\/AKT\/mTOR signaling promotes an M1 macrophage switch by repressing the ATF3-CXCL8 axis in Ewing sarcoma","volume":"555","author":"Palombo","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2026.102866_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100419","article-title":"Targeting the IGF\/PI3K\/mTOR pathway and AXL\/YAP1\/TAZ pathways in primary bone cancer","volume":"33","author":"Truong","year":"2022","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.tranon.2026.102866_bib0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41698-021-00177-0","article-title":"Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target","volume":"5","author":"Seligson","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.tranon.2026.102866_bib0018","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1038\/sj.onc.1207081","article-title":"Rapamycin induces the fusion-type independent downregulation of the EWS\/FLI-1 proteins and inhibits Ewing\u2019s sarcoma cell proliferation","volume":"22","author":"Mateo-Lozano","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2026.102866_bib0019","first-page":"160","article-title":"Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing Family of tumors","volume":"39","author":"Zenali","year":"2009","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.tranon.2026.102866_bib0020","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1158\/1078-0432.CCR-18-0372","article-title":"A combination CDK4\/6 and IGF1R inhibitor strategy for ewing sarcoma","volume":"25","author":"Guenther","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0021","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1158\/0008-5472.CAN-12-1944","article-title":"High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing Sarcoma","volume":"73","author":"Crompton","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0022","doi-asserted-by":"crossref","first-page":"30178","DOI":"10.18632\/oncotarget.4903","article-title":"Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1\/CDK4 pathway inhibition in Ewing sarcoma","volume":"6","author":"Kennedy","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.102866_bib0023","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1158\/1541-7786.MCR-08-0054","article-title":"EWS-Fli1 up-regulates expression of the aurora A and aurora B kinases","volume":"6","author":"Wakahara","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0024","doi-asserted-by":"crossref","first-page":"8770","DOI":"10.1158\/0008-5472.CAN-10-1093","article-title":"Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas","volume":"70","author":"Potratz","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0025","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/1078-0432.CCR-17-0375","article-title":"High-throughput chemical screening identifies focal adhesion kinase and aurora kinase B inhibition as a synergistic treatment combination in ewing Sarcoma","volume":"25","author":"Wang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0026","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell\u2013like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tranon.2026.102866_bib0027","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","article-title":"Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells","volume":"5","author":"Tibes","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2026.102866_bib0028","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-0716-1064-0_9","article-title":"Reverse phase protein arrays","volume":"2237","author":"Davis","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tranon.2026.102866_bib0029","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","article-title":"Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences","volume":"35","author":"Zhu","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.tranon.2026.102866_bib0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.tranon.2026.102866_bib0031","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Cancer Cell."},{"key":"10.1016\/j.tranon.2026.102866_bib0032","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing Sarcoma: current management and future approaches through collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102866_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2022.06.002","article-title":"TK216 targets microtubules in Ewing sarcoma cells","volume":"29","author":"Povedano","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.tranon.2026.102866_bib0034","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nm.1983","article-title":"Small molecule selected to disrupt oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits Ewing\u2019s Sarcoma","volume":"15","author":"Erkizan","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102866_bib0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.18632\/oncotarget.454","article-title":"Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1","volume":"3","author":"Barber-Rotenberg","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.102866_bib0036","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00020","article-title":"Open-label, multicenter, phase I\/II, first-in-Human trial of TK216: a first-generation EWS::FLI1 fusion protein antagonist in ewing Sarcoma","author":"Meyers","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102866_bib0037","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/15592294.2020.1805678","article-title":"Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein","volume":"16","author":"Theisen","year":"2021","journal-title":"Epigenetics"},{"key":"10.1016\/j.tranon.2026.102866_bib0038","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-14-0072","article-title":"Reversible LSD1 inhibition interferes with global EWS\/ETS transcriptional activity and impedes ewing sarcoma tumor growth","volume":"20","author":"Sankar","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0039","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.11514","article-title":"Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed\/refractory Ewing sarcoma","volume":"39","author":"Reed","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102866_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.11508","article-title":"SARC037: phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed\/refractory Ewing sarcoma (ES)","volume":"42","author":"Grohar","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102866_bib0041","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","article-title":"Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus","volume":"76","author":"Harlow","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0042","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1158\/1078-0432.CCR-18-3511","article-title":"Trabectedin inhibits EWS-FLI1 and evicts SWI\/SNF from chromatin in a schedule dependent manner","volume":"25","author":"Harlow","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0043","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-13-0901","article-title":"Dual targeting of EWS-FLI1 activity and the associated DNA damage response with Trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth","volume":"20","author":"Grohar","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0044","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing Sarcoma Family of tumors: results of a phase II Sarcoma Alliance for research through collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102866_bib0045","doi-asserted-by":"crossref","first-page":"15207","DOI":"10.1002\/cam4.6208","article-title":"Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma","volume":"12","author":"Shulman","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.tranon.2026.102866_bib0046","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41588-021-00819-w","article-title":"A first-generation pediatric cancer dependency map","volume":"53","author":"Dharia","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tranon.2026.102866_bib0047","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41598-023-29425-y","article-title":"Targeting mTOR to overcome resistance to hormone and CDK4\/6 inhibitors in ER-positive breast cancer models","volume":"13","author":"Rodriguez","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102866_bib0048","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/2767-9764.CRC-24-0247","article-title":"A kinome-wide synthetic lethal CRISPR\/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4\/CDK6 blockade in HNSCC","volume":"4","author":"Goto","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.tranon.2026.102866_bib0049","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13058-020-01320-8","article-title":"Targeting activated PI3K\/mTOR signaling overcomes acquired resistance to CDK4\/6-based therapies in preclinical models of hormone receptor-positive breast cancer","volume":"22","author":"O\u2019Brien","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.tranon.2026.102866_bib0050","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.18632\/oncotarget.27539","article-title":"Combined inhibition of PIM and CDK4\/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells","volume":"11","author":"Litchfield","year":"2020","journal-title":"Oncotarget"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:28:57Z","timestamp":1787225337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"alternative-id":["S1936523326002032"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102866","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined inhibition of CDK4\/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102866"}}